BridgeMD
Bisphosphonate vs. Placebo Prior to Parathyroidectomy in Primary Hyperparathyroidisme: A Randomized, blinded Placebo-controlled Trial
EU CTIS ID: 2024-520073-13-00
What this study is testing
Our overall aim is a physiological investigation of the effect of bisphosphonate treatment versus placebo at time of parathyroidectomy (PTX) in patients with primary hyperparathyroidism (PHPT) on bone, kidney and the cardiovascular system one-year post-surgery.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Females or males > 40 years
- A diagnosis of hyperparathyroid hypercalcemia due to sporadic PHPT referred to PTX
- aBMD T-score or Z-score ≤ -1 at total hip, femoral neck, distal forearm, or lumbar spine
- 25-hydroxyvitamin D ≥ 50 nmol/l prior to randomization
- Willingness to undergo PTX
You likely can't join if
- Known or suspected familial ethology (e.g., MEN1 or 2)
- Estimated glomerular filtration rate < 35 ml/min
- Known allergy to bisphosphonates
- Planned or recent (within the last 3 months) major dental procedures (e.g., jaw surgery or tooth extraction)
- Chronic or acute disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, cancer) or prior medications (e.g., lithium, glucocorticoids within the last year, antiresorptive or bone anabolic treatment within the last 3 years) known to affect bone metabolism
- Current or planned pregnancy in females
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.